Compound Detail
CHEMBL6068329
PEMETREXED DIPOTASSIUM 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc3)c2c(=O)[nH]1.[K+].[K+]
Basic Information
| ChEMBL ID | CHEMBL6068329 |
| Name | PEMETREXED DIPOTASSIUM |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | YQABXEMTTPRASZ-GXKRWWSZSA-L |
| Therapeutic | ✓ Yes |
| Parent Compound | CHEMBL225072 |
| Active Moiety | CHEMBL225072 |
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
1
Known Names
1
Indications
3
Mechanisms
Molecular Properties
427.4
MW (Da)
0.67
ALogP
6
HBA
6
HBD
191.3
PSA (Ų)
0.29
QED
1
Ro5 Violations
9
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2024 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| GAR transformylase inhibitor | INHIBITOR | Trifunctional purine biosynthetic protein adenosine-3 | ✓ | ✓ |
| Thymidylate synthase inhibitor | INHIBITOR | Thymidylate synthase | ✓ | ✓ |
| Dihydrofolate reductase inhibitor | INHIBITOR | Dihydrofolate reductase | ✓ | ✓ |
Indications
Carcinoma, Non-Small-Cell Lung
Data from ChEMBL 36 via Core Engine